Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Dow
McKesson
Mallinckrodt
Moodys

Last Updated: August 19, 2022

Drugs Containing Excipient (Inactive Ingredient) HYPROMELLOSE 2910


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA-approved (novel) drugs containing HYPROMELLOSE 2910 excipient, and estimated key patent expiration / generic entry dates

Company Tradename Ingredient NDC Excipient Potential Generic Entry
Eli Lilly and Company EFFIENT prasugrel hydrochloride 0002-5121 HYPROMELLOSE 2910
Genentech Inc VALCYTE valganciclovir 0004-0038 HYPROMELLOSE 2910
Genentech Inc XELODA capecitabine 0004-1100 HYPROMELLOSE 2910
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Johnson and Johnson
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.